Xin Lang Cai Jing·2025-06-30 07:09Group 1 - The CSI Medical Index (399989) has shown a strong increase of 1.17%, with significant gains in constituent stocks such as Zhaoyan New Drug (603127) reaching a 10% limit up, and Kylin Pharmaceutical (002821) rising by 5.71% [1] - The leading medical ETF (560260) has experienced a 1.60% increase, with a trading volume of 16.8873 million yuan and an average daily trading volume of 14.2868 million yuan over the past year [1] - The leading medical ETF has achieved a net value increase of 9.14% over the past year, with the highest monthly return since inception being 29.94% and an average monthly return of 8.25% [1] Group 2 - As of May 30, 2025, the top ten weighted stocks in the CSI Medical Index account for 55.09%, with notable companies including WuXi AppTec (603259) and Mindray Medical (300760) [2] - The medical outsourcing service sector is expected to see a rebound, driven by its core position in the industry chain, valuation advantages, and signs of recovery in market conditions [2] - Despite the CRO industry facing challenges, the new listing policies on the Sci-Tech Innovation Board are anticipated to change market perceptions regarding the future development of the CRO sector [2]